Atorvastatin reduces high glucose toxicity in rat peritoneal mesothelial cells

Peritoneal Dialysis International

Volumn 31, Issue 3, 2011, Pages 325-331

  Carrión, Blanca ^a   Pérez Martínez, Francisco C ^a   Monteagudo, Silvia ^a   Pérez Carrión, María D ^a   Gómez Roldán, Carmen ^b   Ceña, Valentín ^c,d   Pérez Martínez, Juan ^b  

^a NanoDrugs SL   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Apoptosis; Atorvastatin; High glucose; Oxidative stress

Indexed keywords

ATORVASTATIN; CASPASE; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; GLUCOSE TOLERANCE TEST; MALE; MESOTHELIUM CELL; NONHUMAN; OXIDATIVE STRESS; PERITONEUM CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

ANIMALS; EPITHELIAL CELLS; GLUCOSE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PERITONEUM; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84856160352     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00164     Document Type: Article

References (48)

1. Mutsaers SE, Wilkosz S. Structure and function of mesothelial cells. Cancer Treat Res 2007; 134:1-19.
2. Alscher DM, Biegger D, Mettang T, van der Kuip H, Kuhlmann U, Fritz P. Apoptosis of mesothelial cells caused by unphysiological characteristics of peritoneal dialysis fluids. Artif Organs 2003; 27:1035-40.
3. Mortier S, De Vriese AS, Lameire N. Recent concepts in the molecular biology of the peritoneal membrane-implications for more biocompatible dialysis solutions. Blood Purif 2003; 21:14-23.
4. Ahmad M, Shah H, Pliakogiannis T, Oreopoulos DG. Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions. Int Urol Nephrol 2007; 39:299-312.
5. Boulanger E, Wautier MP, Gane P, Mariette C, Devuyst O, Wautier JL. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004; 19:2208-16.
6. Sharifi AM, Mousavi SH, Farhadi M, Larijani B. Study of high glucose-induced apoptosis in PC12 cells: role of Bax protein. J Pharmacol Sci 2007; 104:258-62.
7. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41:1280-5.
8. Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl 1999; 71:S134-6.
9. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33:1569-82.
10. Calabrò P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 2005; 20:541-6.
11. Paoletti R, Bolego C, Cignarella A. Lipid and non-lipid effects of statins. Handb Exp Pharmacol 2005; (170):365-88.
12. Haslinger B, Goedde MF, Toet KH, Kooistra T. Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int 2002; 62:1611-19.
13. Haslinger B, Kleemann R, Toet KH, Kooistra T. Simvastatin suppresses tissue factor expression and increases fibrinolytic activity in tumor necrosis factor-alpha-activated human peritoneal mesothelial cells. Kidney Int 2003; 63:2065-74.
14. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20:556-62.
15. Essig M, Nguyen G, Prié D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83:683-90.
16. Mussoni L, Banfi C, Sironi L, Arpaia M, Tremoli E. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost 2000; 84:59-64.
17. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 2000; 152:359-66.
18. Grip O, Janciauskiene S, Lindgren S. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 2000; 410:83-92.
19. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterolmevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-32.
20. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103:2248-53.
21. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17:265-72.
22. Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105:1756-9.
23. Hjelle JT, Golinska BT, Waters DC, Steidley KR, McCarroll DR, Dobbie JW. Isolation and propagation in vitro of peritoneal mesothelial cells. Perit Dial Int 1989; 9:341-7.
24. Shostak A, Pivnik E, Gotloib L. Cultured rat mesothelial cells generate hydrogen peroxide: a new player in peritoneal defense? J Am Soc Nephrol 1996; 7:2371-8.
25. Ha H, Lee HB. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20(Suppl 2):S15-18.
26. Dendorfer A, Heidbreder M, Hellwig-Bürgel T, Jöhren O, Qadri F, Dominiak P. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic Biol Med 2005; 38:117-24.
27. Vorobiov M, Malki M, Shnaider A, Basok A, Rogachev B, Lewis EC, et al. Erythropoietin prevents dialysis fluid-induced apoptosis of mesothelial cells. Perit Dial Int 2008; 28:648-54.
28. d-glucose in human endothelial cells. Diabetes 2001; 50:1472-81.
29. Posadas I, Vellecco V, Santos P, Prieto-Lloret J, Ceña V. Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line. Br J Pharmacol 2007; 150:577-85.
30. Simoncini S, Sapet C, Camoin-Jau L, Bardin N, Harlé JR, Sampol J, et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int Immunol 2005; 17:489-500.
31. Hufnagel G, Michel C, Vrtovsnik F, Queffeulou G, Kossari N, Mignon F. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant 2000; 15:684-8.
32. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61:1469-74.
33. Saltissi D, Westhuyzen J, Morgan C, Healy H. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clin Exp Nephrol 2006; 10:201-9.
34. Paraskevas KI. Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. Int Urol Nephrol 2008; 40:165-70.
35. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-407.
36. Xu ZG, Kim KS, Park HC, Choi KH, Lee HY, Han DS, et al. High glucose activates the p38 MAPK pathway in cultured human peritoneal mesothelial cells. Kidney Int 2003; 63:958-68.
37. Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999; 103:185-95.
38. Schaefer CA, Kuhlmann CR, Weiterer S, Fehsecke A, Abdallah Y, Schaefer C, et al. Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis 2006; 185:290-6.
39. Chen Q, Stone PR, McCowan LM, Chamley LW. Phagocytosis of necrotic but not apoptotic trophoblasts induces endothelial cell activation. Hypertension 2006; 47:116-21.
40. Mrugacz M, Zak J, Bakunowicz-Lazarczyk A, Wysocka J, Kaczmarski M. ICAM-1 expression on conjunctival epithelial cells in patients with cystic fibrosis. Cytometry B Clin Cytom 2007; 72:204-8.
41. Sato K, Nuki T, Gomita K, Weyand CM, Hagiwara N. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 2010; 213:33-9.
42. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 1997; 7:831-6.
43. Seliger SL, Stehman-Breen CO. Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 2003; 16:179-85.
44. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003; 18:967-76.
45. Sauter M, Cohen CD, Wörnle M, Mussack T, Ladurner R, Sitter T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells. Perit Dial Int 2007; 27:167-72.
46. Schilte MN, Loureiro J, Keuning ED, ter Wee PM, Celie JW, Beelen RH, et al. Long-term intervention with heparins in a rat model of peritoneal dialysis. Perit Dial Int 2009; 29:26-35.
47. Nishimura H, Ikehara O, Naito T, Higuchi C, Sanaka T. Evaluation of taurine as an osmotic agent for peritoneal dialysis solution. Perit Dial Int 2009; 29:204-16.
48. Aarons CB, Cohen PA, Gower A, Reed KL, Leeman SE, Stucchi AF, et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 2007; 245:176-84.